{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-259009","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2022-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.407165+00:00","generated_at":"2026-06-23T04:37:39.889961+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin cuts ~120 jobs, expects $50M annual savings to reinvest","bullets":["Workforce reduction of ~120 employees; pre-tax charges of $20-25M in Q3/Q4 2022.","Expected annualized cost savings ~$50M; savings to be reinvested in operations to boost profitability.","Majority of reductions announced Oct 6, 2022; substantially complete by Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-259009","json":"https://secwatch.observer/filing/0001193125-22-259009.json","markdown":"https://secwatch.observer/filing/0001193125-22-259009.md","text":"https://secwatch.observer/filing/0001193125-22-259009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312522259009/0001193125-22-259009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312522259009/d383407d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:37:39.889961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}